VKC
MCID: VRN004
MIFTS: 47

Vernal Keratoconjunctivitis (VKC)

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Vernal Keratoconjunctivitis

MalaCards integrated aliases for Vernal Keratoconjunctivitis:

Name: Vernal Keratoconjunctivitis 52 58
Keratoconjunctivitis, Vernal 71
Keratoconjunctivitis Vernal 54
Spring Catarrh 58
Vkc 52

Characteristics:

Orphanet epidemiological data:

58
vernal keratoconjunctivitis
Inheritance: Not applicable; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 58  
Rare eye diseases


External Ids:

ICD10 via Orphanet 33 H16.2
UMLS via Orphanet 72 C0022577
Orphanet 58 ORPHA70476
UMLS 71 C0022577

Summaries for Vernal Keratoconjunctivitis

NIH Rare Diseases : 52 Vernal keratoconjunctivitis (VKC) is a chronic, severe allergy that affects the surfaces of the eyes. It most commonly occurs in boys living in warm, dry climates. Attacks associated with VKC are common in the spring (hence the name "vernal") and summer but often reoccur in the winter. Signs and symptoms usually begin before 10 years of age and may include hard, cobblestone-like bumps (papillae) on the upper eyelid; sensitivity to light; redness; sticky mucus discharge; and involuntary blinking or spasms of the eyelid (blepharospasm). The condition usually subsides at the onset of puberty. It is caused by a hypersensitivity (allergic reaction) to airborne-allergens. Management focuses on preventing "flare ups" and relieving the symptoms of the condition.

MalaCards based summary : Vernal Keratoconjunctivitis, also known as keratoconjunctivitis, vernal, is related to papillary conjunctivitis and cytokine deficiency. An important gene associated with Vernal Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Histamine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and skin, and related phenotypes are photophobia and pruritus

Wikipedia : 74 Vernal keratoconjunctivitis (VKC) is a recurrent, bilateral, and self-limiting inflammation of... more...

Related Diseases for Vernal Keratoconjunctivitis

Diseases related to Vernal Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
# Related Disease Score Top Affiliating Genes
1 papillary conjunctivitis 30.7 IL4 CCL24 CCL11
2 cytokine deficiency 30.7 IL5 IL13
3 vernal conjunctivitis 30.5 RNASE3 IL4 IGHE
4 giant papillary conjunctivitis 30.4 RNASE3 IL4 CCL24 CCL11
5 atopic keratoconjunctivitis 30.2 RNASE3 IL5 IL4 IGHE
6 keratoconjunctivitis 29.8 RNASE3 IL5 IL4 IL13 CCL5 CCL24
7 pollen allergy 29.8 RNASE3 IL5 IL13
8 eye disease 29.6 IL5 IL4 IL13 CCL5 CCL11
9 allergic conjunctivitis 29.3 RNASE3 IL5 IL4 IL13 IGHE CCL11
10 immune deficiency disease 29.0 IL4 IL13 CCL5
11 autoimmune disease 29.0 IL5 IL4 IL13 CCL5
12 conjunctivitis 29.0 RNASE3 IL5 IL4 IL13 IGHE CCL24
13 ige responsiveness, atopic 29.0 RNASE3 IL5 IL4 IL13 IGHE IGES
14 proteasome-associated autoinflammatory syndrome 1 28.9 RNASE3 IL5 IL4 IL13 CCL5 CCL11
15 psoriasis 28.9 IL5 IL4 IL13 CCL5
16 conjunctival disease 28.8 RNASE3 IL5 IL4 IL13 CCL5 CCL11
17 chronic conjunctivitis 28.5 RNASE3 IL5 IL4 IL13 IGHE CCL11
18 rhinitis 28.1 RNASE3 IL5 IL4 IL13 IGHE CCL5
19 dermatitis 28.1 RNASE3 IL5 IL4 IL13 IGHE CCL5
20 allergic asthma 27.5 RNASE3 IL5 IL4 IL13 IGHE CCL5
21 dermatitis, atopic 27.1 RNASE3 IL5 IL4 IL13 IGHE IGES
22 hypereosinophilic syndrome 27.0 RNASE3 IL5 IL4 IL13 IGHE IGES
23 allergic hypersensitivity disease 27.0 RNASE3 IL5 IL4 IL13 IGHE IGES
24 allergic rhinitis 26.9 RNASE3 IL5 IL4 IL13 IGHE IGES
25 asthma 26.5 RNASE3 IL5 IL4 IL13 IGHE IGES
26 keratoconus 10.9
27 keratitis, hereditary 10.9
28 steroid-induced glaucoma 10.6
29 keratopathy 10.6
30 punctate epithelial keratoconjunctivitis 10.5
31 corneal ulcer 10.5
32 limbal stem cell deficiency 10.5
33 yemenite deaf-blind hypopigmentation syndrome 10.5
34 astigmatism 10.5
35 cataract 10.5
36 intraocular pressure quantitative trait locus 10.4
37 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.4
38 trachoma 10.4
39 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
40 ptosis 10.4
41 hypopyon 10.4
42 chlamydia 10.4
43 irregular astigmatism 10.4
44 thyroiditis 10.4
45 ocular hypertension 10.4
46 loeffler endocarditis 10.3 RNASE3 IL5
47 disseminated eosinophilic collagen disease 10.3 RNASE3 IL5
48 adhesive otitis media 10.3 RNASE3 CCL11
49 scabies 10.3 IL5 CCL11
50 wells syndrome 10.3 RNASE3 IL5

Graphical network of the top 20 diseases related to Vernal Keratoconjunctivitis:



Diseases related to Vernal Keratoconjunctivitis

Symptoms & Phenotypes for Vernal Keratoconjunctivitis

Human phenotypes related to Vernal Keratoconjunctivitis:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 photophobia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000613
2 pruritus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000989
3 corneal neovascularization 58 31 hallmark (90%) Very frequent (99-80%) HP:0011496
4 lacrimation abnormality 58 31 hallmark (90%) Very frequent (99-80%) HP:0000632
5 abnormal conjunctiva morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0000502
6 allergy 58 31 hallmark (90%) Very frequent (99-80%) HP:0012393
7 abnormal sclera morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0000591
8 punctate keratitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0011859
9 scarring 58 31 frequent (33%) Frequent (79-30%) HP:0100699
10 abnormality of the cornea 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Vernal Keratoconjunctivitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.02 CCL11 CCL24 IL13 IL4 IL5

Drugs & Therapeutics for Vernal Keratoconjunctivitis

Drugs for Vernal Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
4
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
7
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
8 Immunosuppressive Agents Phase 4
9 Calcineurin Inhibitors Phase 4
10 Immunologic Factors Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Respiratory System Agents Phase 4
13 Neurotransmitter Agents Phase 4
14 Histamine H1 Antagonists Phase 4
15 Histamine Antagonists Phase 4
16 Autonomic Agents Phase 4
17 Isospaglumic acid Phase 4
18
Histamine Phosphate Phase 4 51-74-1 65513
19 Neuroprotective Agents Phase 4
20 Bronchodilator Agents Phase 4
21 Protective Agents Phase 4
22 Anti-Allergic Agents Phase 4
23 Ophthalmic Solutions Phase 4
24 Anti-Infective Agents Phase 4
25 Pharmaceutical Solutions Phase 4
26 Dermatologic Agents Phase 4
27 Cyclosporins Phase 4
28 Antifungal Agents Phase 4
29 Antirheumatic Agents Phase 4
30 Anti-Bacterial Agents Phase 4
31 Antiemetics Phase 4
32 HIV Protease Inhibitors Phase 4
33
protease inhibitors Phase 4
34 Gastrointestinal Agents Phase 4
35 Anti-Inflammatory Agents Phase 4
36 BB 1101 Phase 4
37 Hormone Antagonists Phase 4
38 Antineoplastic Agents, Hormonal Phase 4
39 glucocorticoids Phase 4
40 Hormones Phase 4
41
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
42 Acidophilus Phase 2, Phase 3
43 Antipruritics Phase 3
44 Antibodies, Monoclonal Phase 1
45 Immunoglobulin G Phase 1
46 Immunoglobulins Phase 1
47 Antibodies Phase 1
48
Tacrolimus Approved, Investigational 104987-11-3 445643 439492 6473866

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
3 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
4 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
5 Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients Completed NCT00567918 Phase 3 FK506
6 A Randomized, Placebo-controlled, Double-masked Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Vernal Keratoconjunctivitis Completed NCT00567762 Phase 3 FK506;placebo
7 A Double-blind Comparison of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drops in the Treatment of Vernal Keratoconjunctivits (VKC) Completed NCT01068054 Phase 2, Phase 3 tacrolimus;cyclosporins
8 A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoconjunctivitis With Severe Keratitis Completed NCT01751126 Phase 3 NOVA22007 ''Ciclosporin'';Placebo
9 Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Lactobacillus Rhamnosus GG Treatment in Preventing Vernal Keratoconjunctivitis VKC) Relapses. Completed NCT00445120 Phase 2, Phase 3 Lactobacillus Rhamnosus GG;placebo (sugar)
10 Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC Completed NCT00328653 Phase 2, Phase 3 cyclosporine
11 Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase. Completed NCT00426023 Phase 3 Cyclosporine A 0,05% eye drop;ketotifen fumarate 0.025% eye drops
12 A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis Completed NCT03379311 Phase 1 AK002
13 Cytokine Assay in Tears of Healthy Children and With Vernal Keratocunjonctivitis: Case Control Study and Monitoring of Cases at 6 Months Unknown status NCT02057822
14 Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Steroid Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis Recruiting NCT03557203
15 The Expression Levels of Diadenosine Polyphosphates and Mucin in Mechanical Stress-related Ocular Surface Disorders Recruiting NCT03731624

Search NIH Clinical Center for Vernal Keratoconjunctivitis

Genetic Tests for Vernal Keratoconjunctivitis

Anatomical Context for Vernal Keratoconjunctivitis

MalaCards organs/tissues related to Vernal Keratoconjunctivitis:

40
Eye, T Cells, Skin, Thyroid, Testes, Lung, Endothelial

Publications for Vernal Keratoconjunctivitis

Articles related to Vernal Keratoconjunctivitis:

(show top 50) (show all 697)
# Title Authors PMID Year
1
Nerve growth factor modulates toll-like receptor (TLR) 4 and 9 expression in cultured primary VKC conjunctival epithelial cells. 54 61
19844589 2009
2
Tearfilm immunoglobulin E (IgE) level in vernal keratoconjunctivitis by ELISA. 54 61
20071840 2009
3
Evaluation of eotaxin-1, -2, and -3 protein production and messenger RNA expression in patients with vernal keratoconjunctivitis. 54 61
19333691 2009
4
Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva. 54 61
17653039 2007
5
Tryptase increases proliferative activity of human conjunctival fibroblasts through protease-activated receptor-2. 54 61
16303958 2005
6
Ocular allergic disease. 54 61
15349048 2004
7
Tear chymase in vernal keratoconjunctivitis. 54 61
15512949 2004
8
The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis. 54 61
14597036 2003
9
Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis. 54 61
14501439 2003
10
Synergistic effect of TNF-alpha and either IL-4 or IL-13 on VCAM-1 expression by cultured human corneal fibroblasts. 54 61
12883351 2003
11
Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. 54 61
12824251 2003
12
Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. 54 61
12623809 2003
13
IL-4-induced cell proliferation and production of extracellular matrix proteins in human conjunctival fibroblasts. 54 61
12589780 2003
14
High level of Fc epsilon receptor I-bindable immunoglobulin E in the tear fluid and increased immunoglobulin E-saturated cells in the giant papillae of vernal keratoconjunctivitis patients. 54 61
12225812 2002
15
Nerve growth factor and asthma. 54 61
12144547 2002
16
Expression of chemokine receptors in vernal keratoconjunctivitis. 54 61
11673306 2001
17
Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage. 54 61
11588428 2001
18
Gelatinase B in vernal keratoconjunctivitis. 54 61
11594952 2001
19
Expression of CD23/CD21 and CD40/CD40 ligand in vernal keratoconjunctivitis. 54 61
11339595 2001
20
Chemokines in the limbal form of vernal keratoconjunctivitis. 54 61
11090473 2000
21
Synergistic induction of eotaxin expression in human keratocytes by TNF-alpha and IL-4 or IL-13. 54 61
10798661 2000
22
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 54 61
10682966 2000
23
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 54 61
10606937 2000
24
Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. 54 61
10469030 1999
25
Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. 54 61
10224366 1999
26
Increased plasma levels of substance P in vernal keratoconjunctivitis. 54 61
9331280 1997
27
Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. 54 61
9135403 1997
28
ICAM-1 expression in corneal epithelium of a patient with vernal keratoconjunctivitis: case report. 54 61
8985642 1997
29
Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis. 54 61
7586697 1995
30
Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. 54 61
7657550 1995
31
Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. 54 61
8588697 1995
32
Collagen types I and III in giant papillae of vernal keratoconjunctivitis. 54 61
7612563 1995
33
IgE, IgE receptors, and other immunocytochemical markers in atopic and nonatopic patients with vernal keratoconjunctivitis. 54 61
7777271 1995
34
Vernal keratoconjunctivitis: a model of 5q cytokine gene cluster disease. 54 61
7613225 1995
35
Increased serum levels of eosinophil cationic protein and eosinophil-derived neurotoxin (protein X) in vernal keratoconjunctivitis. 54 61
7800361 1994
36
Comment on: "Safety and Efficacy of Supratarsal Triamcinolone for Treatment of Vernal Keratoconjunctivitis in Ireland". 61
31725700 2020
37
Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis. 61
31055451 2020
38
Air pollution significantly associated with severe ocular allergic inflammatory diseases. 61
31796815 2019
39
Role of ocular cytology in vernal keratoconjunctivitis. 61
31804769 2019
40
First report of traumatic scleral rupture after penetrating keratoplasty. 61
31701505 2019
41
12-Month Results of Cyclosporine A Cationic Emulsion in a Randomized, Study in Patients With Pediatric Vernal Keratoconjunctivitis. 61
31770513 2019
42
Allergic eye disease in children and adolescents seeking eye care in India: Electronic medical records driven big data analytics report II. 61
31476516 2019
43
Pathogenesis and complications of chronic eye rubbing in ocular allergy. 61
31343437 2019
44
Neurotrophic factors and nerve growth factor in ocular allergy. 61
31145195 2019
45
Gonioscopy-assisted Transluminal Trabeculotomy in a Pediatric Patient With Steroid-induced Glaucoma. 61
31574020 2019
46
Standard cross-linking protocol versus accelerated and transepithelial cross-linking protocols for treatment of paediatric keratoconus: a 2-year comparative study. 61
31654497 2019
47
A clinical study to describe the corneal topographic pattern and estimation of the prevalence of keratoconus among diagnosed cases of vernal keratoconjunctivitis. 61
31719737 2019
48
Topical tacrolimus for allergic eye diseases. 61
31169598 2019
49
Pattern of steroid misuse in vernal keratoconjunctivitis resulting in steroid induced glaucoma and visual disability in Indian rural population: An important public health problem in pediatric age group. 61
31546501 2019
50
Adult Vernal Keratoconjunctivitis: Clinical and biochemical profile of a rare disease. 61
31276829 2019

Variations for Vernal Keratoconjunctivitis

Expression for Vernal Keratoconjunctivitis

Search GEO for disease gene expression data for Vernal Keratoconjunctivitis.

Pathways for Vernal Keratoconjunctivitis

Pathways related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 RNASE3 IL5 IL4 IL13 IGHE CCL5
2
Show member pathways
13.55 IL5 IL4 IL13 CCL5 CCL24 CCL11
3
Show member pathways
13.42 IL5 IL4 IL13 CCL5 CCL24 CCL11
4
Show member pathways
13.3 IL5 IL4 IL13 CCL5 CCL24 CCL11
5
Show member pathways
13.17 IL5 IL4 IL13 CCL5 CCL24 CCL11
6
Show member pathways
13.12 IL5 IL4 IL13 IGHE CCL5 CCL11
7
Show member pathways
13.07 IL5 IL4 IL13 CCL5 CCL24 CCL11
8
Show member pathways
12.62 RNASE3 IL5 IL4 IL13 CCL11
9
Show member pathways
12.41 IL5 IL4 IL13 IGHE
10
Show member pathways
12.19 IL4 IGHE CCL11
11
Show member pathways
12.15 IL5 IL4 IL13 CCL11
12
Show member pathways
12.14 CCL5 CCL24 CCL11
13
Show member pathways
12.13 IL5 IL4 IL13
14
Show member pathways
12.12 CCL5 CCL24 CCL11
15 11.73 IL4 IL13 IGHE CCL11
16 11.66 IL5 IL4 IL13
17 11.64 IL5 IL4 IL13
18 11.36 IL4 IL13 CCL5
19 11.36 IL5 IL4 IGHE CCL11
20 11.2 IL4 IL13 CCL5 CCL24 CCL11
21 11.15 IL5 IL4
22 11.14 IL5 IL4 IL13
23 11.12 IL5 IL4 IL13 CCL11
24 11.07 IL5 IL4 IL13
25 11 IL5 IL4 IL13
26 10.82 IL5 IL4 IL13 CCL5 CCL11
27 10.7 IL5 IL4 IL13 CCL5 CCL24 CCL11

GO Terms for Vernal Keratoconjunctivitis

Cellular components related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 RNASE3 IL5 IL4 IL13 CCL5 CCL24
2 extracellular region GO:0005576 9.23 RNASE3 IL5 IL4 IL13 IGHE CCL5

Biological processes related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.76 CCL5 CCL24 CCL11
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.74 CCL5 CCL24 CCL11
3 chemotaxis GO:0006935 9.72 CCL5 CCL24 CCL11
4 cellular response to tumor necrosis factor GO:0071356 9.71 CCL5 CCL24 CCL11
5 cellular response to interferon-gamma GO:0071346 9.7 CCL5 CCL24 CCL11
6 neutrophil chemotaxis GO:0030593 9.69 CCL5 CCL24 CCL11
7 cellular response to interleukin-1 GO:0071347 9.67 CCL5 CCL24 CCL11
8 chemokine-mediated signaling pathway GO:0070098 9.65 CCL5 CCL24 CCL11
9 inflammatory response GO:0006954 9.65 IL5 IL13 CCL5 CCL24 CCL11
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 IL4 IL13 CCL5
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 IL4 IL13
12 monocyte chemotaxis GO:0002548 9.58 CCL5 CCL24 CCL11
13 positive regulation of JAK-STAT cascade GO:0046427 9.56 IL5 CCL5
14 positive regulation of B cell proliferation GO:0030890 9.54 IL5 IL4 IL13
15 lymphocyte chemotaxis GO:0048247 9.5 CCL5 CCL24 CCL11
16 negative regulation of complement-dependent cytotoxicity GO:1903660 9.43 IL4 IL13
17 cytokine-mediated signaling pathway GO:0019221 9.43 IL5 IL4 IL13 IGHE CCL5 CCL11
18 eosinophil chemotaxis GO:0048245 9.33 CCL5 CCL24 CCL11
19 immune response GO:0006955 9.17 IL5 IL4 IL13 IGHE CCL5 CCL24

Molecular functions related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor ligand activity GO:0048018 9.37 CCL24 CCL11
2 chemokine activity GO:0008009 9.33 CCL5 CCL24 CCL11
3 cytokine receptor binding GO:0005126 9.32 IL4 IL13
4 CCR3 chemokine receptor binding GO:0031728 9.26 CCL24 CCL11
5 CCR chemokine receptor binding GO:0048020 9.13 CCL5 CCL24 CCL11
6 cytokine activity GO:0005125 9.1 IL5 IL4 IL13 CCL5 CCL24 CCL11

Sources for Vernal Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....